We can’t show the full text here under this license. Use the link below to read it at the source.
Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes
Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes
AI simplified
Abstract
Tirzepatide resulted in greater mean reductions in HbA1c and weight compared to semaglutide after 12 months.
- In patients who had not previously used GLP-1 receptor agonists, those on tirzepatide experienced a mean HbA1c reduction of -1.3%, compared to -0.9% for those on semaglutide.
- Patients with prior GLP-1 receptor agonist use on tirzepatide had a mean HbA1c reduction of -0.9%, while those on semaglutide saw a reduction of -0.6%.
- Weight loss after 12 months was greater in the tirzepatide group, with a mean reduction of -10.2 kg in naïve patients versus -6.1 kg in semaglutide patients.
- Non-naïve patients on tirzepatide lost an average of -7.9 kg, compared to -3.7 kg for those on semaglutide.
- Both findings were statistically significant (p < 0.001).
AI simplified
Key numbers
-1.3%
HbA1c Reduction (Naïve)
Mean change in HbA1c for tirzepatide vs. semaglutide
-10.2 kg
Weight Loss (Naïve)
Mean weight reduction for tirzepatide vs. semaglutide
-0.9%
HbA1c Reduction (Non-Naïve)
Mean change in HbA1c for tirzepatide vs. semaglutide